This is the jumping-off point for all TLS drug development projects.
From here, you'll be able to access Project Portfolio for each drug candidate, where you'll have the opportunity to provide high-level input via TLS Protocol Builders, our crowdsourcing survey tool to develop clinical protocols . Each project has its own Protocol Builder that asks specific questions relating to each compound’s indication and trial design. Click on a project heading for more information.
Indication Finder: A Repurposing Hunt We invite you to participate in a unique exercise. The U.S. National Center for Advancing Translational Sciences (NCATS) has posted a list of 58 compounds that are available for repurposing studies. We need your help to determine if some of these compounds might help patients in other indications and be good candidates for the open innovation approach to drug development. Intrigued? Cick here to find out more!
|Kiacta in Sarcoidosis|
Why Study Kiacta in Sarcoidosis?
TLS has begun a collaboration with Auven Therapeutics to develop Kiacta in sarcoidosis. Kiacta is a compound developed by Auven Therapeutics for AA amyloidosis and sarcoidosis. TLS is assisting Auven on the sarcoidosis aspect of the program.
|Lisinopril in Multiple Sclerosis|
Why lisinopril in multiple sclerosis (MS)?
Please take part in designing an innovative clinical study of lisinopril in MS.Protocol Builder Results
|Telemedicine Acceptance in IBD|
Why study telemedicine acceptance in IBD?
Transparency Life Sciences, in collaboration with Genentech, a member of the Roche Group, is conducting a pilot study in patients with inflammatory bowel disease.
|Metformin in Prostate Cancer|
Why metformin in prostate cancer?
Please take part in designing an innovative clinical study of metformin in patients with recurrent prostate cancer, as manifested by a rising PSA blood test (biochemical recurrence), after surgery or radiation.Protocol Builder Results